Beam Therapeutics Reports Improved Patient-Reported Outcomes in Risto-cel Sickle Cell Trial
Bitget2026/11/04 14:10- Beam Therapeutics will present updated Phase 1/2 BEACON trial results for sickle cell therapy risto-cel at ASH on December 12, 2026.
- Initial patient-reported outcomes showed early, sustained improvements in physical function, pain and overall well-being compared with baseline.
- A U.S. biologics license application for the investigational cell therapy is expected as early as year-end 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Intel's decline narrows, CEO spends nearly 10 million dollars to increase stock holdings
Intel disclosed that CEO Pat Gelsinger purchased 150,000 shares of Intel common stock on the open market on November 2nd, at a weighted average price of $64.7312 per share, with a transaction amount of approximately $9.71 million. The purchase was made through a family trust, and after the transaction, the trust's Intel holdings increased to 1.4647 million shares, up around 11.4% from before the transaction. Following the announcement, Intel’s share price briefly rallied, narrowing its decline to 1.2% before retreating again.
Euro: ECB rate hike bets support gains against US Dollar - Scotiabank
Crypto prices
More
